Oncology Priority Drug List

A. Injections:

1. Arsenic trioxide

2. L- Asparaginase

3. PEG- Asperaginase

4. Azacitidinea/Decitabineb

5. BCGc

6. Bendamustine

7. Bleomycin

8. Bortezomib

9. Calcium folinate (Leucovorin)

10. Carboplatin

11. Cisplatin

12. Cladaribine

13. Cyclophosphamide

14. Cytarabine

15. Dacarbazine

16. Dactinomycin

17. Daunorubicin

18. Docetaxel

19. Doxorubicin

20. Epirubicin

21. Etoposide

22. Filgrastim

23. Fludarabine

24. Fluorouracil

25. Fulvestrant

26. Gemcitabine

27. Goserelin

28. Ifosfamide with Mesna

29. Irinotecan

30. Melphalan

31. Methotrexate

32. Mitomycin

33. Nivolumabd/ Pembrolizumabe

34. Octreotide

35. Oxaliplatin

36. Paclitaxel

37. Pemetrexed

38. Rituximab

39. Topotecanf

40. Trastuzumab

41. Vinblastine

42. Vincristine

43. Vinorelbine

44. Zoledronic acid

Oncology Priority Drug List

B. Tablets:

1. Abiraterone Acetate

2. All-trans retinoic acid

3. Anastrozole

4. Bicalutamide

5. Calcium folinate (Leucovorin)

6. Capecitabine

7. Chlorambucil

8. Cyclophosphamide

9. Dasatinib

10. Erlotinib

11. Etoposide

12. Exemestane

13. Gefitinib

14. Hydroxyurea

15. Imatinib

16. Lenalidomide

17. Melphalan

18. Mercaptopurine

19. Methotrexate

20. Morphine tablets (IR & SR)

21. Nilotinib

22. Osimertinibg

23. Palbociclibh/ Ribociclibj

24. Pazopanib

25. Procarbazine

26. Sorafenib

27. Sunitinib

28. Tamoxifen

29. Temozolomide

30. Thalidomide

a,b For the use in MDS or elderly AML patients who are not eligible for chemotherapy. There is no preference of one drug over the other.

c Powder for intravesical use

d,e For the use in metastatic melanoma. There is no preference of one drug over the other.

f For the use in ovarian carcinoma progressing on platinum based chemotherapy

g For the adjuvant use and in metastatic setting of Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor (EGFR) mutation. The EGFR mutation detection report need to be attached with the MSD request.

h,j For the use in Hormone Receptor positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer following Progression after first line endocrine therapy. There is no preference of one drug over the other